NewAmsterdam Pharma (NAMS) Assets Average (2022 - 2026)

NewAmsterdam Pharma has disclosed Assets Average across 4 years of filings, most recently posting $751.0 million for Q1 2026.

• Assets Average for Q1 2026 came in at $751.0 million, down 10.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $751.0 million (down 10.76% YoY), and the FY2025 annual result was $817.0 million, up 34.84% from the prior year.
• Assets Average came in at $751.0 million for Q1 2026 at NewAmsterdam Pharma, down from $777.9 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $841.5 million in Q1 2025 to a low of $305.4 million in Q4 2022.
• The 4-year median for Assets Average is $701.4 million (2024), against an average of $627.3 million.
• Across the five-year window, Assets Average jumped 101.43% in 2025 and slipped 10.76% in 2026, its largest moves.
• NewAmsterdam Pharma's Assets Average stood at $305.4 million in 2022, then surged by 113.48% to $651.9 million in 2024, then increased by 19.32% to $777.9 million in 2025, then slipped by 3.46% to $751.0 million in 2026.
• The last three Assets Average figures came in at $751.0 million (Q1 2026), $777.9 million (Q4 2025), and $800.8 million (Q3 2025), per Business Quant data.